J&J drops Phase III MDD programme due to lack of efficacy
Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ‘insufficient efficacy …
Post
-
-
ImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agent
ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the hypoxia reversal agent, …
-
How to integrate patients into clinical research with cohesive strategies
As patient voices get amplified across platforms, finding effective ways to further enhance participation and let patient-driven inputs drive clinical …
-
The trillion-dollar opportunity in women’s health
Closing the gap in health interventions between men and women could add $1tn to the global gross domestic product (GDP) …
-
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trial
Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development …
-
Hutchmed concludes enrolment in Phase II trial of fanregratinib for IHCC
Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic cholangiocarcinoma (IHCC) individuals …
-
Everest Medicines begins dosing in mRNA cancer vaccine trial
Everest Medicines has dosed the first subject with EVM16, the company’s personalised messenger ribonucleic acid (mRNA) cancer vaccine, in the …
-
Project Optimus: The evolution of dose optimisation in oncology
In 2021, the Project Optimus initiative was launched by the US Food and Drug Administration’s (FDA) Oncology Center of Excellence, …
-
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up …
-
Men urged to book prostate screenings with GPs due to unreliable at-home tests
Prostate cancer is the most common cancer among men in the UK. Leading data and analytics company GlobalData epidemiologists currently …
-
Beckley Psytech completes subjects’ enrolment for Phase IIb trial of TRD therapy
Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected BPL-003 …
-
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 (VMAT2) inhibitor, …
-
Persica’s antibiotic-based drug alleviates lower back pain in Phase Ib trial
Persica Pharmaceuticals will advance its antibiotic-based drug to registrational studies after a Phase Ib study found that the therapy alleviated …
-
Abbott’s brain stimulation trial for depression kicks off at Mount Sinai
New York City’s Mount Sinai has become the first hospital in the US to perform a deep brain stimulation (DBS) …
-
Beyond compliance: The strategic role of PASS in rare disease therapy success
By taking a more strategic approach to PASS, you can secure long-term market access, gain regulatory trust, and provide critical …
